"This merger is a compelling opportunity for our stockholders," stated Michael Richman, the CEO of NextCure, as the biotech company announced a dramatic 300% spike in its stock price on Tuesday. This sudden surge follows the announcement of an all-stock merger with Avere Therapeutics, bolstered by a significant $320 million private financing deal. The combined entity, scheduled to operate under the Avere name and trade on Nasdaq with the ticker AVRX, is expected to finalize in the latter half of 2026.
The private placement includes $251 million in convertible notes, which will convert to common stock upon the merger’s completion. Fairmount and Hansoh Pharmaceutical led this financing round, with contributions from several notable investors including Venrock Healthcare Capital Partners and Wellington Management. This funding aims to facilitate advanced clinical trials for AVR-001, a promising therapy targeting conditions like psoriasis and ulcerative colitis.
Despite this explosive growth, NextCure’s stock has seen an overall decline of roughly 84% year-to-date, leaving it with a market capitalization of about $7.87 million before the merger announcement. Avere Therapeutics is developing AVR-001, an oral IL-23 receptor antagonist with the potential to address significant inflammatory conditions. This merger allows NextCure shareholders to hold about 1.21% of the new company and earn contingent value rights from any future monetization of NextCure's pipeline for a period of two years post-deal closure.
Trading activity on Tuesday was notably high, with over 44 million shares changing hands well above the average of around 37,000 shares daily over the last three months. As the market reacts to this new development, it remains essential to consider how this merger may impact the broader biotech sector and individual investors.
This article is for informational purposes only and does not constitute financial advice.
